Clinical trials recruiting for NSCLC (Advanced Non-small Cell Lung Cancer)

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A 2-part Phase 1/2 Open-label Trial on ODM-212
  NCT07563738 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
  NCT06946927 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
  NCT07361237 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Retrospective Real-World Study Based on RATIONALE-307
  NCT07478809 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
  NCT06706076 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
  NCT07250386 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
  NCT07705334 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
  NCT06604689 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
  NCT07371663 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer
  NCT06896890 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
  NCT07288632 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer
  NCT07259447 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
  NCT07528274 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
  NCT06775743 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC
  NCT07356544 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
  NCT07001618 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
  NCT07158489 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
  NCT05856981 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
  NCT07348965 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
  NCT07330596 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
  NCT06881784 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 153 locations
• Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
  NCT06992739 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for NSCLC (Advanced Non-small Cell Lung Cancer) often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for NSCLC (Advanced Non-small Cell Lung Cancer) trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.